These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16971666)

  • 1. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
    Popat S; Chen Z; Zhao D; Pan H; Hearle N; Chandler I; Shao Y; Aherne W; Houlston R
    Ann Oncol; 2006 Dec; 17(12):1810-7. PubMed ID: 16971666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
    Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
    Jensen SA; Vainer B; Sørensen JB
    Int J Cancer; 2007 Feb; 120(3):694-701. PubMed ID: 17096352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
    Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
    Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
    Broll R; Busch P; Duchrow M; Oevermann E; Schwandner O; Farke S; Bruch HP; Windhövel U
    Int J Colorectal Dis; 2005 Mar; 20(2):94-102. PubMed ID: 15309465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
    Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
    Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
    J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Lin LW; Lai PS; Chen YY; Chen CY
    Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
    Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
    Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
    BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
    Aguiar S; Lopes A; Soares FA; Rossi BM; Ferreira FO; Nakagawa WT; Carvalho AL; Filho WJ
    Eur J Surg Oncol; 2005 Oct; 31(8):863-8. PubMed ID: 15923105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Rogowski W; Domagala W
    Pathol Oncol Res; 2016 Jul; 22(3):601-8. PubMed ID: 26831819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.